| Epstein–Barr virus infection is not a characteristic feature of multiple sclerosis brain SN Willis, C Stadelmann, SJ Rodig, T Caron, S Gattenloehner, ... Brain 132 (12), 3318-3328, 2009 | 320 | 2009 |
| The intersection of Epstein-Barr virus with the germinal center JE Roughan, DA Thorley-Lawson Journal of virology 83 (8), 3968-3976, 2009 | 178 | 2009 |
| Germinal center B cells latently infected with Epstein-Barr virus proliferate extensively but do not increase in number JE Roughan, C Torgbor, DA Thorley-Lawson Journal of virology 84 (2), 1158-1168, 2010 | 87 | 2010 |
| Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells JE Roughan, KM Reardon, KE Cogburn, H Quendler, PJ Pockros, M Law Clinical and Vaccine Immunology 19 (7), 1027-1037, 2012 | 31 | 2012 |
| Mechanisms of allorecognition G Benichou, Y Akiyama, J Roughan, Y Iwamoto, G Tocco Immunobiology of organ transplantation, 107-137, 2004 | 5 | 2004 |
| Transplantation tolerance to non-inherited maternal antigens (NIMA) in a MHC class I transgenic mouse model Y Akiyama, S Caucheteux, Y Iwamoto, J Roughan, ... Human immunology 10 (64), S129, 2003 | 1 | 2003 |
| What’s Next for Viral Vectors Within Gene Therapy Clinical Trials J Roughan Form Bio, 2023 | | 2023 |
| Achieving Operational Marketing Excellence in a Regulated Industry For Maximum Growth and Return on Investment J Roughan Sciencia Consulting, 2020 | | 2020 |
| Putting your best B cell forward: a novel HIV vaccine design approach J Roughan Scientific American, 2013 | | 2013 |
| Solving Gene Therapy Product Development Challenges Through Analytical Standardization J Roughan Form Bio, 0 | | |
